APOE and atherosclerosis: In apolipoprotein E-deficient (Apoe−/−) mice, a 1 week nanoimmunotherapy treatment regimen achieved significant anti-inflammatory effects, due to the reduced migration capacity of plaque monocytes; this highlights the translational potential of this strategy for the treatment of atherosclerosis [87].